Thanks for that update RNC, Could you clarify the price...

First 24 Last

Share
Profile

Follow
aussienorm

974 Posts.

7

30/07/17

17:35

Post #: 26168316
Share

Originally posted by RNClarke ↑

Listened in to the Investor call last night and am feeling very bullish with ePat. Went for a good 1.5hrs. Some points for those who missed out:

- World first medically approved app using AI to detect and monitor level of pain. Not solely for dementia patients, also for carers of adults who are not able to communicate or express pain.
- Wants this to turn into a “mini Cochlear” and Daffas is very excited to be commercialising this. He has taken numerous devices to market in both diabetes care and cardiovascular products and knows how to navigate this ship.
- Aged care facilities are ready to go and are wanting to start implementing EPT right now. They have 2-3 facilities they are creating agreements for “ePat in Practise” which will then be revenue generating in Q4.
- Patents: Once granted will be for 15-20 years.
- Its already published on the App Store, the iOS app is working very well already. Not available to the public just yet.
- The recent Alzheimer's Journal Article on ePat was a great achievement, comes out in August/September and will be for everyone to read. Will significantly help with FDA submission.
- Australia is essentially the pilot market, the initial customers want to build usage and support.
- Pricing most likely between $5-$10 and will be per patient or number of beds in a facility.
- Daffas kept using the comparison between ePat and Roche, and their diabetes care and the similar economics. Daffas was the chief marketer for AccuChek which is one of the leading diabetes monitoring brand. He knows well and truly how ePat needs to scale and where to move.
- Childrens app is being compiled, this will really bring the blue sky potential. It is a lot more complex however due to childrens faces changing rapidly but they are on track.
- At the end I asked about the nViso license agreement extension. Essentially its in a bit of ping pong between lawyers etc. The current agreement doesn't expire for a while but they hope to have it sorted by Q4. Their relationship is very much aligned. One of the CEOs will be coming down in August and Daffas is hoping to conduct roadshows with the CEO of the software provider.

Someone mentioned the possibility of a TO, whilst its early stages, a company like Roche or a medical diagnostics company would be a great match down the track.

Expand

Thanks for that update RNC,
Could you clarify the price structure if possable.......is it $5-$10 per patient or per use by the patient or per month. I realise you cannot be definitive but your best guess would be appreciated .GLTA

EPT Price at posting: 4.2¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 10 more messages in this thread...

First 24 Last

Add PCK (ASX) to my watchlist

(20min delay)
Last 3.1¢		Change 0.001(3.33%)		Mkt cap ! $49.11M

Open	High	Low	Value	Volume
3.1¢	3.1¢	3.1¢	$1.974K	63.67K

Buyers (Bids)

No.	Vol.	Price($)
10	450435	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.2¢	122917	4

View Market Depth

No.	Vol.	Price($)
10	450435	0.030
5	6607448	0.029
1	350000	0.028
3	488344	0.027
4	1600000	0.026

Price($)	Vol.	No.
0.032	122917	4
0.033	126161	2
0.034	79638	2
0.035	125000	1
0.036	322246	2

Last trade - 12.27pm 07/10/2024 (20 minute delay)

PCK (ASX) Chart

Thanks for that update RNC, Could you clarify the price...

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for that update RNC, Could you clarify the price...

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News